These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1118 related articles for article (PubMed ID: 34526033)

  • 1. The efficacy of corticosteroids therapy in patients with moderate to severe SARS-CoV-2 infection: a multicenter, randomized, open-label trial.
    Ghanei M; Solaymani-Dodaran M; Qazvini A; Ghazale AH; Setarehdan SA; Saadat SH; Ghobadi H; Hoseininia S; Elahikhah M; Samadi AH; Imani Y; Vahedi E; Babamahmoodi F; Rostami FT; Ardebili MHA; Ansarifar A; Golmaei FF; Asadollah A
    Respir Res; 2021 Sep; 22(1):245. PubMed ID: 34526033
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of Interferon Beta 1a, compared to Interferon Beta 1b and the usual therapeutic regimen to treat adults with moderate to severe COVID-19: structured summary of a study protocol for a randomized controlled trial.
    Irvani SSN; Golmohammadi M; Pourhoseingholi MA; Shokouhi S; Darazam IA
    Trials; 2020 Jun; 21(1):473. PubMed ID: 32493468
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The efficacy and safety of Ivermectin in patients with mild and moderate COVID-19: A structured summary of a study protocol for a randomized controlled trial.
    Hosseini FS; Malektojari A; Ghazizadeh S; Hassaniazad M; Davoodian P; Dadvand H; Nikpoor AR; Nikoofal-Sahlabadi S; Kahoori S; Sepandi M; Hassanipour S; Fathalipour M
    Trials; 2021 Jan; 22(1):4. PubMed ID: 33397429
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of antiviral combination therapy in symptomatic patients of Covid-19 infection - a randomised controlled trial (SEV-COVID Trial): A structured summary of a study protocol for a randomized controlled trial.
    Panda PK; Bandyopadhyay A; Singh BC; Moirangthem B; Chikara G; Saha S; Bahurupi YA
    Trials; 2020 Oct; 21(1):866. PubMed ID: 33081849
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of Favipiravir in moderate to severe SARS-CoV-2 pneumonia.
    Solaymani-Dodaran M; Ghanei M; Bagheri M; Qazvini A; Vahedi E; Hassan Saadat S; Amin Setarehdan S; Ansarifar A; Biganeh H; Mohazzab A; Khalili D; Hosein Ghazale A; Reza Heidari M; Taheri A; Khoramdad M; Mahdi Asadi M; Nazemieh M; Varshochi M; Abbasian S; Bakhtiari A; Mosaed R; Hosseini-Shokouh SJ; Shahrokhi M; Yassin Z; Ali Zohal M; Qaraati M; Rastgoo N; Sami R; Javad Eslami M; Asghari A; Namazi M; Ziaie S; Jafari-Moghaddam R; Kalantari S; Memarian M; Khodadadi J; Hossein Afshari M; Momen-Heravi M; Behzadseresht N; Reza Mobayen A; Mozafari A; Movasaghi F; Haddadzadeh Shoushtari M; Moazen J
    Int Immunopharmacol; 2021 Jun; 95():107522. PubMed ID: 33735712
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An investigation into the beneficial effects of high-dose interferon beta 1-a, compared to low-dose interferon beta 1-a (the base therapeutic regimen) in moderate to severe COVID-19: A structured summary of a study protocol for a randomized controlled l trial.
    Alavi Darazam I; Hatami F; Rabiei MM; Pourhoseingholi MA; Moradi O; Shokouhi S; Hajesmaeili MR; Shabani M; Irvani SSN
    Trials; 2020 Oct; 21(1):880. PubMed ID: 33106183
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparing outcomes of hospitalized patients with moderate and severe COVID-19 following treatment with hydroxychloroquine plus atazanavir/ritonavir.
    Rahmani H; Davoudi-Monfared E; Nourian A; Nabiee M; Sadeghi S; Khalili H; Abbasian L; Ghiasvand F; Seifi A; Hasannezhad M; Ghaderkhani S; Mohammadi M; Yekaninejad MS
    Daru; 2020 Dec; 28(2):625-634. PubMed ID: 32857301
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The clinical value of two combination regimens in the Management of Patients Suffering from Covid-19 pneumonia: a single centered, retrospective, observational study.
    Vahedi E; Ghanei M; Ghazvini A; Azadi H; Izadi M; Panahi Y; Fathi S; Salesi M; Saadat SH; Ghazale AH; Rezapour M; Mozafari A; Zand N; Parsaei MR; Ranjkesh MH; Jafari R; Movaseghi F; Darabi E
    Daru; 2020 Dec; 28(2):507-516. PubMed ID: 32562159
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early experimental COVID-19 therapies: associations with length of hospital stay, mortality and related costs.
    Vernaz N; Agoritsas T; Calmy A; Gayet-Ageron A; Gold G; Perrier A; Picard F; Prendki V; Reny JL; Samer C; Stirnemann J; Vetter P; Zanella MC; Zekry D; Baggio S
    Swiss Med Wkly; 2020 Dec; 150():w20446. PubMed ID: 33382449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the efficacy and safety of favipiravir and interferon compared to lopinavir/ritonavir and interferon in moderately ill patients with COVID-19: a structured summary of a study protocol for a randomized controlled trial.
    Hassaniazad M; Bazram A; Hassanipour S; Fathalipour M
    Trials; 2020 Oct; 21(1):886. PubMed ID: 33109246
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of nitazoxanide plus atazanavir/ritonavir for the treatment of moderate to severe COVID-19 (NACOVID): A structured summary of a study protocol for a randomised controlled trial.
    Olagunju A; Fowotade A; Olagunoye A; Ojo TO; Adefuye BO; Fagbamigbe AF; Adebiyi AO; Olagunju OI; Ladipo OT; Akinloye A; Adeagbo BA; Onayade A; Bolaji OO; Happi C; Rannard S; Owen A
    Trials; 2021 Jan; 22(1):3. PubMed ID: 33397457
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Umifenovir in hospitalized moderate to severe COVID-19 patients: A randomized clinical trial.
    Alavi Darazam I; Shokouhi S; Mardani M; Pourhoseingholi MA; Rabiei MM; Hatami F; Shabani M; Moradi O; Gharehbagh FJ; Irvani SSN; Amirdosara M; Hajiesmaeili M; Rezaei O; Khoshkar A; Lotfollahi L; Gachkar L; Dehbsneh HS; Khalili N; Soleymaninia A; Kusha AH; Shoushtari MT; Torabinavid P
    Int Immunopharmacol; 2021 Oct; 99():107969. PubMed ID: 34273635
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outpatient treatment of COVID-19 with steroids in the phase of mild pneumonia without the need for admission as an opportunity to modify the course of the disease: A structured summary of a randomised controlled trial.
    Saiz-Rodríguez M; Peña T; Lázaro L; González Á; Martínez A; Cordero JA; Vicente JT; Richard F; Coma MJ; de Frutos M; Labrador J; Pueyo A
    Trials; 2020 Jul; 21(1):632. PubMed ID: 32646502
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial.
    Furtado RHM; Berwanger O; Fonseca HA; Corrêa TD; Ferraz LR; Lapa MG; Zampieri FG; Veiga VC; Azevedo LCP; Rosa RG; Lopes RD; Avezum A; Manoel ALO; Piza FMT; Martins PA; Lisboa TC; Pereira AJ; Olivato GB; Dantas VCS; Milan EP; Gebara OCE; Amazonas RB; Oliveira MB; Soares RVP; Moia DDF; Piano LPA; Castilho K; Momesso RGRAP; Schettino GPP; Rizzo LV; Neto AS; Machado FR; Cavalcanti AB;
    Lancet; 2020 Oct; 396(10256):959-967. PubMed ID: 32896292
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparing the effectiveness of Atazanavir/Ritonavir/Dolutegravir/Hydroxychloroquine and Lopinavir/Ritonavir/Hydroxychloroquine treatment regimens in COVID-19 patients.
    Kalantari S; Fard SR; Maleki D; Taher MT; Yassin Z; Alimohamadi Y; Minaeian S
    J Med Virol; 2021 Dec; 93(12):6557-6565. PubMed ID: 34255369
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results.
    ; Pan H; Peto R; Henao-Restrepo AM; Preziosi MP; Sathiyamoorthy V; Abdool Karim Q; Alejandria MM; Hernández García C; Kieny MP; Malekzadeh R; Murthy S; Reddy KS; Roses Periago M; Abi Hanna P; Ader F; Al-Bader AM; Alhasawi A; Allum E; Alotaibi A; Alvarez-Moreno CA; Appadoo S; Asiri A; Aukrust P; Barratt-Due A; Bellani S; Branca M; Cappel-Porter HBC; Cerrato N; Chow TS; Como N; Eustace J; García PJ; Godbole S; Gotuzzo E; Griskevicius L; Hamra R; Hassan M; Hassany M; Hutton D; Irmansyah I; Jancoriene L; Kirwan J; Kumar S; Lennon P; Lopardo G; Lydon P; Magrini N; Maguire T; Manevska S; Manuel O; McGinty S; Medina MT; Mesa Rubio ML; Miranda-Montoya MC; Nel J; Nunes EP; Perola M; Portolés A; Rasmin MR; Raza A; Rees H; Reges PPS; Rogers CA; Salami K; Salvadori MI; Sinani N; Sterne JAC; Stevanovikj M; Tacconelli E; Tikkinen KAO; Trelle S; Zaid H; Røttingen JA; Swaminathan S
    N Engl J Med; 2021 Feb; 384(6):497-511. PubMed ID: 33264556
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and effectiveness of high-dose vitamin C in patients with COVID-19: a randomized open-label clinical trial.
    JamaliMoghadamSiahkali S; Zarezade B; Koolaji S; SeyedAlinaghi S; Zendehdel A; Tabarestani M; Sekhavati Moghadam E; Abbasian L; Dehghan Manshadi SA; Salehi M; Hasannezhad M; Ghaderkhani S; Meidani M; Salahshour F; Jafari F; Manafi N; Ghiasvand F
    Eur J Med Res; 2021 Feb; 26(1):20. PubMed ID: 33573699
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proactive Prophylaxis With Azithromycin and HydroxyChloroquine in Hospitalised Patients With COVID-19 (ProPAC-COVID): A structured summary of a study protocol for a randomised controlled trial.
    Sivapalan P; Ulrik CS; Bojesen RD; Lapperre TS; Eklöf JV; Håkansson KEJ; Browatzki A; Tidemansen C; Wilcke JT; Janner J; Gottlieb V; Meteran H; Porsbjerg C; Madsen BL; Moberg M; Pedersen L; Benfield TL; Lundgren JD; Knop FK; Biering-Sørensen T; Ghanizada M; Sonne TP; Bødtger UCS; Jensen SG; Rasmussen DB; Brøndum E; Tupper OD; Sørensen SW; Alstrup G; Laursen CB; Møller UW; Sverrild A; Jensen JS
    Trials; 2020 Jun; 21(1):513. PubMed ID: 32522282
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Trial of Favipiravir and Hydroxychloroquine combination in Adults Hospitalized with moderate and severe Covid-19: A structured summary of a study protocol for a randomised controlled trial.
    Bosaeed M; Mahmoud E; Hussein M; Alharbi A; Alsaedy A; Alothman A; Aljeraisy M; Alqahtani H; Nashabat M; Almutairi B; Almaghaslah M; Aldibasi O; AlJohani S; Bouchama A; Arabi Y; Alaskar A
    Trials; 2020 Oct; 21(1):904. PubMed ID: 33129363
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 56.